Entrada Therapeutics director granted 19,000 options

Entrada Therapeutics director Radhakrishnan Maha received a grant of 19,000 stock options.

Rhea-AI Filing Summary

Entrada Therapeutics director Radhakrishnan Maha received a grant of 19,000 stock options. Each option allows the purchase of one share of common stock at an exercise price of $5.97 per share and was granted at no cost.

The options vest and become exercisable on the earlier of the one-year anniversary of June 10, 2026 or Entrada’s next annual meeting of stockholders, and expire on June 10, 2036. After this grant, Maha holds 19,000 stock options directly.

Insider Trade Summary

Grant/Award: 19,000 shares

Grant/Award 1 txn

Insider Radhakrishnan Maha

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	19,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 19,000 contracts (Direct)

Footnotes (1)

1. F1. The shares subject to this option shall vest and become exercisable on the earlier of (i) the one-year anniversary of June 10, 2026 or (ii) the Issuer's next annual meeting of stockholders.

Key Figures

Options granted: 19,000 options Exercise price: $5.97 per share Underlying shares: 19,000 shares +2 more

5 metrics

Options granted 19,000 options Stock Option (Right to Buy) granted on June 10, 2026

Exercise price $5.97 per share Exercise price for underlying common stock

Underlying shares 19,000 shares Common Stock underlying the options

Post-grant derivative holdings 19,000 options Total stock options held after this grant

Expiration date June 10, 2036 Option expiration for the grant

Key Terms

Stock Option (Right to Buy), exercise price, vesting, annual meeting of stockholders

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 5.9700"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"The shares subject to this option shall vest and become exercisable on the earlier of (i) the one-year anniversary of June 10, 2026 or (ii) the Issuer's next annual meeting of stockholders."

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

annual meeting of stockholders financial

"the Issuer's next annual meeting of stockholders."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Entrada Therapeutics (TRDA) report for Radhakrishnan Maha?

Entrada Therapeutics reported that director Radhakrishnan Maha received a grant of 19,000 stock options. These options give the right to buy common shares at $5.97 each, were granted at no cost, and vest based on time or the next shareholder meeting.

What is the exercise price of the new Entrada Therapeutics (TRDA) stock options?

The granted stock options have an exercise price of $5.97 per share. This means Maha can later buy Entrada Therapeutics common stock at $5.97, regardless of the future market price, once the options vest and before they expire in 2036.

When do Radhakrishnan Maha’s Entrada Therapeutics (TRDA) options vest?

The 19,000 stock options vest on the earlier of the one-year anniversary of June 10, 2026 or Entrada Therapeutics’ next annual meeting of stockholders. Vesting must occur before the options become exercisable for purchasing common shares at the fixed price.

When do the newly granted Entrada Therapeutics (TRDA) stock options expire?

The stock options granted to Radhakrishnan Maha expire on June 10, 2036. After that date, any unexercised options are no longer valid, so they must be exercised between vesting and this expiration date to acquire Entrada Therapeutics common stock.

How many Entrada Therapeutics (TRDA) options does Radhakrishnan Maha hold after this grant?

After the reported grant, Radhakrishnan Maha holds 19,000 stock options directly. Each option is linked to one share of Entrada Therapeutics common stock, giving him a potential future claim on 19,000 shares if all options eventually vest and are exercised.

Did Radhakrishnan Maha buy or sell Entrada Therapeutics (TRDA) shares in this Form 4?

This Form 4 reports a grant of stock options, not open-market buying or selling of shares. Maha acquired 19,000 options as a compensation-related award, with no cash purchase and no sale of Entrada Therapeutics common stock in this transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/12/2026 - 05:05 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Radhakrishnan Maha

(Last) (First) (Middle)

C/O ENTRADA THERAPEUTICS, INC.

ONE DESIGN CENTER PLACE, SUITE 17-500

(Street)

BOSTON MASSACHUSETTS 02210

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Entrada Therapeutics, Inc. [ TRDA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$5.97	06/10/2026		A		19,000		(1)	06/10/2036	Common Stock	19,000	$0	19,000	D

Explanation of Responses:

1. The shares subject to this option shall vest and become exercisable on the earlier of (i) the one-year anniversary of June 10, 2026 or (ii) the Issuer's next annual meeting of stockholders.

Remarks:

	/s/ Jared Cohen, as Attorney-in-Fact	06/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)